Cemiplimab and Chemo for Advanced Squamous Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a combination of an immunotherapy drug (cemiplimab) plus chemotherapy for advanced squamous non-small cell lung cancer. Researchers want to see if this treatment works better in people whose tumors have a certain enzyme level.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called squamous non-small cell lung cancer.
- Your cancer has spread to other parts of the body (Stage IV) or has come back after treatment.
- You have not had any chemotherapy or immunotherapy for cancer that has spread.
- Your doctor has checked the PD-L1 level of your tumor.
- You are in good overall health (able to take care of yourself and do light work).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called cemiplimab (an immunotherapy) for people with advanced lung cancer that has high PD-L1 levels. It uses a simple blood test to track how well the treatment is working.
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
This trial tests a combination of immunotherapy (cemiplimab) and chemotherapy for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. It looks at whether this treatment works better when certain immune cells in the blood are high.
This trial tests giving Cemiplimab, an immunotherapy drug that helps your immune system fight cancer, before surgery to remove early stage non-small cell lung cancer. It aims to see if this approach can improve outcomes for people with small tumors that are more aggressive based on PET scan activity or cell appearance.
This trial tests a new combination of drugs (THIO and cemiplimab) against standard chemotherapy for people with advanced non-small cell lung cancer who have already tried two prior treatments including immunotherapy and platinum chemo. The goal is to see if the combination helps control the cancer better.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Hear when a new Advanced Squamous Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.